Communiqués de pressePosters MaaT Pharma annonce la publication dans Nature Communications des résultats de l’essai clinique ODYSSEE de Phase 1/2. L'essai de la thérapie autologue de restauration du microbiote, MaaT011, a atteint ses objectifs principaux…MaaT Pharmamai 25, 2021
Posters EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics MaaT Pharmaaoût 28, 2020
Posters ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics MaaT Pharmadécembre 7, 2019
Posters An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog MaaT Pharmajuillet 24, 2019
Posters HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct MaaT Pharmajuin 1, 2019
Posters ASH 2018: The Odyssee study: Results of a prospective multicenter trial MaaT Pharmadécembre 2, 2018
Posters EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases MaaT Pharmaseptembre 18, 2018
Posters Gram proportion determination in complex ecosystems using flow cytometry A first glimpse of the evolution of a complex ecosystem during in vitro fermentation can…MaaT Pharmajuin 20, 2018
Posters ASH 2017: Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in AML patients undergoing intensive treatment (ODYSSEE study): First results of a prospective multicenter trial MaaT Pharmadécembre 10, 2017